CytoSorbents
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CytoSorbents - overview
Established
1997
Location
-, NJ, US
Primary Industry
Medical Devices & Equipment
About
CytoSorbents develops innovative blood purification technologies, focusing on critical health challenges through advanced medical devices designed for use in critical care settings. Founded in 1997 in the United States, CytoSorbents specializes in blood purification and has gone public as of December 2014. The company is co-led by CEOs Oliver Lupoli and Phillip Chan, both of whom bring extensive experience in the healthcare sector. CytoSorbents primarily offers a range of advanced blood purification technologies, with its flagship product being the CytoSorb® adsorber.
This device utilizes proprietary biocompatible, highly porous polymer bead technology to selectively remove harmful substances from the bloodstream, addressing critical health issues such as septic shock, liver failure, and other conditions that lead to dangerous levels of inflammatory mediators. The CytoSorb adsorber has been integrated into various therapeutic applications in critical care, cardiovascular, liver, and kidney treatments, aiming to restore physiological balance and reduce organ dysfunction. The company also provides complementary products like PuriFi, an ex vivo organ perfusion platform designed to mitigate inflammation, and VetResQ, tailored for veterinary health emergencies. CytoSorbents products are marketed across over 75 countries, including major healthcare markets in Europe, Asia, and North America, catering to hospitals and healthcare professionals focused on improving patient outcomes in acute care settings.
In the most recent fiscal year of 2022, CytoSorbents generated revenue of USD 34. 69 mn, while experiencing an EBITDA of USD -30. 39 mn. The company generates revenue through the direct sale of its blood purification products to hospitals and healthcare providers, emphasizing a B2B transaction model.
CytoSorbents engages in partnerships and collaborations with healthcare institutions to implement its technologies, facilitating bulk purchasing agreements and training programs for medical staff. Revenue is derived from the sale of individual CytoSorb adsorbers and associated platforms, with pricing structures reflecting the critical nature of the treatments involved. CytoSorbents positions its offerings as vital components in healthcare practices, reinforcing its role in improving patient survival rates and recovery outcomes. CytoSorbents aims to expand its product offerings and market reach, focusing on the development of new blood purification technologies tailored for emerging medical conditions.
The company is also targeting expansion into new markets in Asia and Europe by 2025, leveraging recent funding raised through its IPO on December 23, 2014, totaling USD 10. 20 mn to support these initiatives.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment
Website
www.cytosorbents.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
CytoSorbents - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 36,078 | 1,342,936 | 2,422,667 | 4,122,825 | 4,791,616 | 9,527,843 | 15,150,754 | 22,503,908 | 24,949,473 | 41,004,601 | 43,165,527 | 34,688,809 | - | - | - |
| % Revenue Growth (YoY) | - | 3622.3% | 80.4% | 70.2% | 16.2% | 98.8% | 59.0% | 48.5% | 10.9% | 64.4% | 5.3% | (19.6%) | - | - | - |
| EBITDA (USD) | (3,452,183) | (2,964,876) | (4,337,633) | (7,014,601) | (9,190,690) | (11,300,032) | (9,542,273) | (15,097,336) | (18,277,326) | (9,386,734) | (21,615,132) | (30,390,250) | - | - | - |
| Operating Income (USD) | (4,436,767) | (3,490,834) | (4,713,231) | (7,278,792) | (9,303,659) | (11,492,125) | (9,842,598) | (15,584,928) | (18,974,064) | (10,370,334) | (22,744,745) | (31,521,879) | - | - | - |
| Operating Margin | (12297.7%) | (259.9%) | (194.5%) | (176.5%) | (194.2%) | (120.6%) | (65.0%) | (69.3%) | (76.0%) | (25.3%) | (52.7%) | (90.9%) | - | - | - |
| % EBITDA Margin | (9568.7%) | (220.8%) | (179.0%) | (170.1%) | (191.8%) | (118.6%) | (63.0%) | (67.1%) | (73.3%) | (22.9%) | (50.1%) | (87.6%) | - | - | - |
| NET Income (USD) | (5,481,648) | (3,663,506) | (4,677,795) | (9,321,672) | (8,131,738) | (11,938,875) | (8,460,799) | (17,211,179) | (19,265,644) | (7,837,188) | (24,558,648) | (32,812,583) | - | - | - |
| % Net Margin | (15193.9%) | (272.8%) | (193.1%) | (226.1%) | (169.7%) | (125.3%) | (55.8%) | (76.5%) | (77.2%) | (19.1%) | (56.9%) | (94.6%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.